What Is Cytokine Release Syndrome (CRS), and How Is It Treated?
In this article
What Is Cytokine Release Syndrome (CRS)?
Cytokine release syndrome (CRS) is a serious condition resulting from excessive, uncontrolled immune activation , with fever, low blood pressure (hypotension), shortness of breath and organ dysfunction .
🧠 How Does CRS Develop?
- Excessive Immune Activation: CAR-T cells, bispecific antibodies such as tarlatamab, or certain immunotherapies strongly activate T cells and/or other immune cells.
- Excessive Cytokine Release: Activated T cells and macrophages release large amounts of IL-6, IL-1, IFN-γ, TNF-α . Normally needed against infection, excessive release produces acytokine storm.
- Inflammation and Vascular Leakage: Widespread inflammation increases vascular permeability, allowing fluid to escape → hypotension and edema.
- Organ Dysfunction: Heart, lungs, liver and kidneys may be affected, causing fever, breathlessness, tachycardia, hypotension and altered consciousness.
🩺 Symptoms
Common Early Symptoms
- Fever ≥38 °C (often the first sign), chills
- Weakness, fatigue, headache
Moderate Symptoms
- Hypotension, tachycardia
- Shortness of breath, breathing difficulty
- Nausea, vomiting; dizziness/lightheadedness
Severe Symptoms
- Confusion, agitation/anxiety
- Coordination and balance problems
- Organ Problems: Heart (arrhythmia, failure), liver (enzymes ↑), kidneys (creatinine ↑, failure)
- Increased oxygen needs; rarely severe, prolonged bleeding
Note: Mild CRS usually begins with fever and fatigue, followed by hypotension, tachycardia or breathlessness as it progresses. Severe CRS can threaten life through altered consciousness and organ dysfunction.
📊 Severity Grades (ASTCT Criteria)
| Grade | Definition: Summary |
|---|---|
| Grade 1 | Fever only |
| Grade 2 | Fever + low-level oxygen support and/or fluid-responsive hypotension |
| Grade 3 | High oxygen needs and/or fluid-resistant hypotension requiring vasopressors |
| Grade 4 | Life-threatening multiorgan failure |
💊 How Is CRS Treated?
Mild CRS (Grade 1–2)
- Supportive Care: IV fluids, fever control with paracetamol
- Empirical antibiotics if concurrent infection is suspected
- Close vital-sign and symptom monitoring
Moderate CRS (Grade 2–3)
- Tocilizumab (IL-6R inhibitor) is first-line; alternative: Siltuximab (IL-6 inhibitor)
- Oxygen; for hypotension, IV fluidsand, if needed, vasopressors
- Close organ function and laboratory monitoring
Severe CRS (Grade 3–4)
- Intensive care management
- Corticosteroids added, such as dexamethasone or methylprednisolone
- High-flow oxygen or mechanical ventilation if needed
- For refractory hypotension, vasopressor support
- Organ support for multiorgan involvement
General Principles: Early recognition and rapid intervention are crucial. With IMDELLTRA® (tarlatamab) or CAR-T, premedication (corticosteroids, antihistamines, antipyretics) and prolonged observation (e.g. 22–24 hours), especially for initial infusions, are recommended. Escalate treatment according to clinical condition, CRS grade and complications.
🛡️ How Can CRS Be Prevented?
Patient Selection
High tumor burden, aggressive disease such as acute leukemia or aggressive lymphoma, and multiple comorbidities increase risk. Assess clinical condition carefully before treatment.
Premedication
- Corticosteroids (e.g. dexamethasone) suppress excessive T-cell activation
- Antihistamine + antipyretic — infusion reaction and fever control
- In step-up protocols (e.g. IMDELLTRA® 1 mg → 10 mg), this is crucial
Close Vital-Sign Monitoring
- During and after infusion, temperature, blood pressure, pulse, respiratory rate and SpO₂ are monitored regularly
- During initial cycles, prolonged hospital observation (e.g. up to 22–24 hours for IMDELLTRA®)
Early Recognition and Rapid Intervention
- Alert the team as soon as CRS symptoms begin: fever, hypotension or breathlessness
- A low threshold for tocilizumab may prevent severe CRS
Drug-Based Prevention
Anti-IL-6/IL-6R agents such as tocilizumab or siltuximab may be given to selected high-risk patients prophylactically or early , potentially reducing CRS severity, particularly with CAR-T and bispecific antibodies.
Summary: CRS management rests on early recognition, grade-based treatment escalation and close monitoring by an experienced team.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.